PYXIS ONCOLOGY INC (PYXS)

US7473241013 - Common Stock

2.04  +0.2 (+10.87%)

After market: 2.0016 -0.04 (-1.88%)

PYXIS ONCOLOGY INC

NASDAQ:PYXS (9/28/2023, 7:09:21 PM)

After market: 2.0016 -0.04 (-1.88%)

2.04

+0.2 (+10.87%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-11 2023-08-11/bmo
Earnings (Next)N/A N/A
Ins Owners25.44%
Inst Owners21.78%
Market Cap89.50M
Shares43.87M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts84
IPO10-08 2021-10-08
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PYXS Daily chart

Company Profile

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The company is headquartered in Boston, Massachusetts and currently employs 72 full-time employees. The company went IPO on 2021-10-08. The firm is focused on developing a multi-modality portfolio of therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The company has developed a portfolio that includes antibody drug conjugate (ADC), product candidates, immuno-oncology (IO), product candidates, and monoclonal antibody (mAb), preclinical discovery programs that it is developing as monotherapies and in combination with other therapies. Its product pipelines include PYX-201, PYX-106 and PYX-107. Its ADC product candidate is PYX-201, an investigational, novel ADC consisting of an Immunoglobulin G1 (IgG1), anti-fibronectin Extradomain-B, mAb site-specifically conjugated to an auristatin derivative via a cathepsin B-cleavable linker. Its IO product candidate is PYX-106, an investigational, fully human IgG1 isotype Siglec-15-targeting antibody designed to block Siglec-15 mediated suppression of T-cell proliferation and function.

Company Info

PYXIS ONCOLOGY INC

321 Harrison Avenue, 11th Floor, Suite 1

Boston MASSACHUSETTS

P: 16174533596.0

Employees: 72

Website: https://pyxisoncology.com/

PYXS News

News Image2 days ago - Pyxis OncologyPyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023
News Image2 days ago - Pyxis OncologyPyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023

BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation...

News Image7 days ago - Levi & Korsinsky, LLPSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ: PYXS)

/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Pyxis Oncology, Inc. (NASDAQ: PYXS) concerning possible breaches of...

News Image9 days ago - Seeking AlphaPyxis Oncology CEO sells shares worth $18.2k - filing (NASDAQ:PYXS)

Pyxis Oncology (PYXS) CEO and president Lara Sullivan disclosed in an SEC filing on Monday after the bell a sale of 8,641 shares of the company at prices ranging from $2.1 and $2.25...

News Imagea month ago - Pyxis OncologyPyxis Oncology to Participate in Two Upcoming Investment Conferences
News Imagea month ago - Pyxis OncologyPyxis Oncology to Participate in Two Upcoming Investment Conferences

BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation...

PYXS Twits

Here you can normally see the latest stock twits on PYXS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example